Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Video Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Advertisement
Advertisement
Trending
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.